Pfizer (PFE) closed the last trading day at $27.66, indicating a change of -1.32% from the end of the previous session. The stock trailed the S&P 500, which posted a daily gain of 0.85%. Meanwhile, the Dow Jones lost 0.09% and the Nasdaq, a tech-heavy index, added 1.53%.
As of today, the pharmaceutical company's shares had lost 1.23% in the last month. In that same time, the medical sector gained 2.46%, while the S&P 500 gained 3.11%.
Pfizer's upcoming earnings release will be of great interest to investors. The company is expected to post an EPS of $0.45, showing a downward movement of 32.84% from the corresponding quarter of the previous year. Meanwhile, the latest consensus estimate predicts revenue to be $13.21 billion, indicating an increase of 3.72% compared to the same quarter last year.
For the full year, Zacks Consensus Estimates are projecting earnings of $2.38 per share and revenue of $60.66 billion, which would represent changes of +29.35% and +3.7%, respectively, from the year former.
Investors should also take note of any recent adjustments to analyst estimates for Pfizer. These reviews typically reflect the latest short-term business trends, which can change frequently. Therefore, positive estimate revisions convey analyst confidence in the company's business performance and earnings potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we have established the Zacks Rank, a proprietary model that considers these estimate changes and provides a working rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an admirable, independently audited track record of outperformance, with #1 stocks contributing an average annual return of +25 % since 1988. Over the past month, the Zacks Consensus EPS estimate moved 0.63% lower. Pfizer is a Zacks Rank #3 (Hold) right now.
From a valuation perspective, Pfizer is currently exchanging hands with a forward P/E ratio of 11.8. For comparison, its industry has an average Forward P/E of 14.38, which means Pfizer is trading at a discount to the group.
Meanwhile, PFE's PEG ratio is currently 1.1. This popular metric is similar to the well-known P/E ratio, except that the PEG ratio also takes into account the company's expected earnings growth rate. Large Cap Pharmaceuticals shares are holding, on average, a PEG ratio of 1.76 based on yesterday's closing prices.
The large-cap pharmaceutical industry is part of the medical sector. With its current Zacks Industry Rank of 149, this industry ranks in the bottom 41% of all industries with over 250.
The Zacks Industry Rank assesses the strength of our various industry groups by determining the average Zacks Rank of the individual stocks that make up the groups. Our research shows that the top 50% of industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics and much more on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today you can download the 7 best stocks for the next 30 days. Click to get this free report
Pfizer Inc. (PFE): Free Stock Analysis Report
To read this article on Zacks.com, click here.
